The brand name for orforglipron is Foundayo. It is a once-daily oral GLP-1 receptor agonist from Eli Lilly and Company, approved by the US Food and Drug Administration on April 1, 2026, for obesity, or overweight with a weight-related condition.
One distinction is especially important: orforglipron is not a peptide. It is a non-peptide small molecule that activates the GLP-1 receptor. Although it belongs to a drug class often associated with peptide medicines, its molecular structure is different.
Understanding that distinction helps clarify what Foundayo is, how its brand name relates to its active ingredient, and why describing it simply as another GLP-1 peptide is inaccurate.
What Is the Brand Name for Orforglipron?
Foundayo is the brand name, while orforglipron is the generic name of the active ingredient. These names refer to the branded medicine and its drug substance, respectively, rather than two different treatments.
The main facts are:
- Brand name: Foundayo, also styled as FOUNDAYO.
- Generic name: Orforglipron.
- Company: Eli Lilly and Company.
- Drug class: GLP-1 receptor agonist.
- Molecular type: Non-peptide small molecule.
- Form: Once-daily oral tablet.
- US approval date: April 1, 2026.
Older articles may describe orforglipron as an investigational or unbranded drug. Those descriptions can reflect an earlier stage of development, but they do not describe its current US regulatory status. When researching the medicine, checking publication dates is important.
Why Orforglipron Is Not a Peptide
The term GLP-1 receptor agonist describes what a medicine does: it activates the glucagon-like peptide-1 receptor. It does not, by itself, establish that the medicine is a peptide.
Peptides consist of amino acids linked together. Orforglipron instead belongs to the category of small-molecule drugs. Its classification as a non-peptide GLP-1 receptor agonist is therefore central to an accurate description of the medicine.
A Receptor Target Is Not a Molecular Structure
Confusion can arise because GLP-1 means glucagon-like peptide-1. However, the word peptide in the receptor name does not mean every drug acting at that receptor must also be a peptide.
A useful distinction is:
- GLP-1 receptor agonist identifies the biological receptor the drug activates.
- Non-peptide small molecule identifies the type of molecule orforglipron is.
- Oral tablet identifies its formulation and route of administration.
These descriptions answer different questions. Foundayo can be a GLP-1 receptor agonist and a non-peptide medicine at the same time. Calling it a peptide because of its receptor target mixes up pharmacology with molecular structure.
Is Foundayo FDA-Approved?
Yes. According to the supplied Lilly approval announcement, the FDA approved Foundayo on April 1, 2026, for obesity, or overweight with a weight-related condition.
This means it should not be described as an unapproved research compound in the United States. Its earlier clinical development remains relevant background, but investigational status and approval status are not interchangeable.
Approval also applies to a defined product and indication. It does not mean every product advertised online using the name orforglipron is equivalent to the approved medicine. Similarly, US approval does not establish authorization or availability in every other country.
When Did Foundayo Launch?
The Drugs.com approval history lists the US launch date as April 9, 2026. This is separate from its FDA approval date.
The distinction matters because regulatory approval and commercial launch are different milestones. Approval establishes authorization for the specified use; launch refers to commercial introduction. Neither milestone guarantees that a particular pharmacy has stock or that an individual insurance plan covers the medicine.
What Did the ATTAIN-1 Trial Report?
The supplied Lilly reference identifies ATTAIN-1 as a 72-week trial involving 3,127 participants. It reports a weight change of −12.4%, or 27.3 pounds, compared with −0.9% for placebo.
These figures describe reported clinical trial findings, not a guaranteed result for an individual. They should not be presented as a prediction of what any particular person will experience.
The trial also does not change the molecular classification of the drug. Orforglipron was studied as a non-peptide small-molecule GLP-1 receptor agonist; the reported outcomes do not make it a peptide or establish that it is interchangeable with other GLP-1 medicines.
For readers comparing treatments, a single trial summary is only part of the evidence. Study populations, methods, endpoints, and safety findings all matter when interpreting results.
Who Developed Orforglipron?
Orforglipron was discovered by Chugai and licensed by Lilly in 2018, according to the supplied Lilly reference.
This explains why both company names may appear in articles about the medicine. Chugai is associated with its discovery, while Lilly is associated with its subsequent development and the Foundayo brand.
The development history also helps connect older research coverage with newer product information. Earlier publications may use only the name orforglipron, whereas current US product coverage may use Foundayo. The naming change does not indicate a different active ingredient.
Important Foundayo Safety Information
Foundayo is a prescription medicine with important safety restrictions. The supplied approval information identifies a warning concerning thyroid C-cell tumors and contraindications involving medullary thyroid carcinoma, or MTC, and multiple endocrine neoplasia syndrome type 2, or MEN2.
These are significant labeling considerations, not minor qualifications. A medicine being available as a tablet does not mean it is risk-free or suitable for everyone.
This article does not provide a complete safety summary, dosing instructions, or individualized treatment advice. The current prescribing information is the appropriate source for the full approved indications, contraindications, warnings, and adverse reactions. A qualified healthcare professional can interpret that information in the context of an individual medical history.
Foundayo Price and Availability
The supplied Drugs.com reference reports self-pay pricing starting at USD 149 per month. That starting figure should not be treated as a universal price or a guarantee of current out-of-pocket cost.
Pricing and access can change. Insurance coverage, program eligibility, pharmacy arrangements, and other conditions may affect what someone pays. A quoted starting price also does not establish that every patient qualifies for the same purchasing option.
Frequently Asked Questions About Orforglipron
Are Foundayo and Orforglipron the Same Thing?
Foundayo is the brand name of the medicine, and orforglipron is its active ingredient. The names describe the branded product and its generic drug substance.
Is Orforglipron a GLP-1 Peptide?
No. Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. Its receptor target does not make its molecular structure a peptide.
Is Foundayo an Injection?
No. Foundayo is an oral tablet described in the supplied approval material as a once-daily medicine. This formulation detail is not a substitute for the prescribing instructions.
Is Orforglipron Still Investigational in the United States?
Not for the approved Foundayo indication. Its FDA approval was announced on April 1, 2026. Older descriptions calling it investigational should be read in their historical context.
The Bottom Line
Orforglipron is marketed as Foundayo, and it is not a peptide. It is an FDA-approved, oral, non-peptide small-molecule GLP-1 receptor agonist. Keeping its brand name, molecular classification, and current approval status separate makes information about this medicine clearer and more accurate.
Sources
